Whistling Past the Graveyard: The Problem with the Per Se Legality Treatment of Pay-For-Delay Settlements
Michael Kades, Nov 01, 2009
Arguably, the most important debate in antitrust jurisprudence involves pay-for-delay patent settlements in which the brand company pays the generic to stay out of the market. As a matter of economics, it will generally be most profitable if the brand and the generic firm avoid the possibility of competition and share the resulting monopoly profits; however, such settlements will reduce competition and increase the costs of drugs. If pay-for-delay settlements are legal, parties will enter them to the detriment of consumers. Current cases, in particular the Tamoxifen and Ciprofloxacin decisions, however, have gone a long way towards adopting just such a standard, a standard that is already having an effect. By adopting an approach without regard to its implications or erroneously suggesting that pay for delay settlements are an ineffective way to delay competition, courts are essentially whistling past the graveyard.
Featured News
Live Nation Faces Growing UK Antitrust Pressure Over Industry Influence
Jul 20, 2026 by
CPI
Buchanan Ingersoll Expands Antitrust Practice With Washington Hire
Jul 20, 2026 by
CPI
China Nears Decision in Antitrust Case Against Trip.com
Jul 20, 2026 by
CPI
EU Intensifies Cartel Probe Into Swiss Chemicals Firm Sika
Jul 20, 2026 by
CPI
X and Major Music Publishers Settle Parallel Copyright and Antitrust Cases
Jul 20, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes